Baillie Gifford & CO Cellectis S.A. Transaction History

Baillie Gifford & CO

$127 Billion
Q4 2024

A detailed history of Baillie Gifford & CO transactions in Cellectis S.A. stock. As of the latest transaction made, Baillie Gifford & CO holds 290,429 shares of CLLS stock, worth $467,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares

290,429

Previous 693,939 58.15%

Holding current value

$467,590

Previous $1.47 Million 64.51%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 31, 2025	SELL	$1.51 - $2.14 $609,300 - $863,511	-403,510 Reduced 58.15%	290,429 $522,000
Q3 2024 Nov 05, 2024	SELL	$1.9 - $2.4 $26,012 - $32,858	-13,691 Reduced 1.93%	693,939 $1.47 Million
Q2 2024 Jul 25, 2024	SELL	$1.86 - $3.35 $222,489 - $400,720	-119,618 Reduced 14.46%	707,630 $1.32 Million
Q1 2024 May 01, 2024	BUY	$2.41 - $3.09 $25,558 - $32,769	10,605 Added 1.3%	827,248 $2.19 Million
Q4 2023 Jan 26, 2024	SELL	$0.97 - $3.55 $336,945 - $1.23 Million	-347,366 Reduced 29.84%	816,643 $2.52 Million
Q3 2023 Nov 13, 2023	SELL	$1.58 - $2.86 $402,879 - $729,262	-254,987 Reduced 17.97%	1,164,009 $1.84 Million
Q2 2023 Jul 28, 2023	SELL	$1.72 - $2.12 $379,948 - $468,308	-220,900 Reduced 13.47%	1,418,996 $2.8 Million
Q1 2023 May 03, 2023	BUY	$1.83 - $3.84 $1.9 Million - $3.99 Million	1,040,000 Added 173.36%	1,639,896 $3.16 Million
Q4 2022 Jan 24, 2023	SELL	$1.85 - $2.6 $349,540 - $491,246	-188,941 Reduced 23.95%	599,896 $1.26 Million
Q3 2022 Oct 27, 2022	SELL	$2.29 - $4.08 $210,897 - $375,747	-92,095 Reduced 10.45%	788,837 $1.81 Million
Q2 2022 Aug 08, 2022	SELL	$2.39 - $4.93 $480,779 - $991,733	-201,163 Reduced 18.59%	880,932 $2.49 Million
Q1 2022 May 05, 2022	BUY	$3.45 - $8.77 $8,914 - $22,661	2,584 Added 0.24%	1,082,095 $4.91 Million
Q4 2021 Jan 20, 2022	BUY	$8.01 - $12.84 $23,917 - $38,340	2,986 Added 0.28%	1,079,511 $8.77 Million
Q3 2021 Oct 19, 2021	BUY	$11.94 - $16.09 $509,276 - $686,286	42,653 Added 4.13%	1,076,525 $13.6 Million
Q2 2021 Aug 02, 2021	BUY	$14.36 - $20.93 $14.8 Million - $21.6 Million	1,033,872 New	1,033,872 $16 Million

Others Institutions Holding CLLS

# of Institutions

Shares Held

10.2M

Call Options Held

5.9K

Put Options Held

1.4K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $73.3M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Cellectis S.A. Transaction History